Weekly Funding Opportunities

[Med Research]

Klingenstein Third Generation Foundation: Increasing Access to Mental Health Care for Children and Adolescents<https://urldefense.com/v3/__https://klingenstein.org/klingenstein-third-generation-foundation/other-grants/applying/__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzeGbj7sI$ >
We are soliciting applications for academic investigators conducting research to demonstrate the benefits of new health care delivery methods or prevention approaches. We are particularly interested in funding applications that build on promising pilot work and aim to develop larger demonstration projects. In particular, the KTGF is most interested in improving access to mental health care for children through the use of novel models or approaches, including (but not limited to) digital technology (e.g. the internet, apps for cell phones), expanding the number of professional and paraprofessional treatment personnel who are trained to deliver mental health services, and delivering care in non-psychiatric settings (e.g., primary care, schools, home, or other novel settings).  Primary outcomes should include the measurement of improved access and/or reduced time to service delivery. We are also interested in the following secondary outcomes: minimizing the burdens and maladaptive behaviors associated with mental health problems in children; decreasing the development of secondary co-morbid disorders, and the development of adverse educational, relational and health outcomes; and improving the functioning of youth and their families. Because parents can be important to the successful treatment of their children, another secondary outcome might include the enhanced ability of parents to facilitate their children’s access to treatment. $100,000 for two-year projects; foundation expects to make up to two awards.
Due January 10, 2021. Med-RA deadline to receive draft documents: December 14 (due to Winter Break).

More than Skin Deep: Mental Health–National Psoriasis Foundation Grants<https://urldefense.com/v3/__https://npf-website.cdn.prismic.io/npf-website/51348ff1-b1b8-4047-9541-6c7bb44d39ea_2021_MoreThanSkinDeep_MentalHealth_RFA.pdf__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzupT7vTc$ >
According to the NPF, those with psoriatic disease are at increased risk of suffering from moderate-severe depression, have higher rates of anxiety, and are at increased risk for suicidality. Stigmatization may also exacerbate self-perception, avoidance behaviors, negative emotions, and maladaptive thought processes leading to increased instance of depression, anxiety, and other affective disorders. The increased incidence of mental health disorders in persons with psoriatic disease has been attributed to the increased stressors of living with a chronic disease, social stigma associated with the disease, and evidence that inflammatory processes in psoriatic disease may also create neurological changes affecting mental health. Current research efforts include looking at ways that the treatment of anxiety and depression may help manage psoriatic disease and how biologic treatments for psoriatic disease impact depression. To answer these and other questions, the foundation seeks grant applications from researchers interested in conducting research focused on mental health and psoriatic disease. Grants of up to $100,000 will be awarded to projects focused on, but not limited to, investigation of psoriatic disease on mental health, as well as interventions for addressing this comorbidity, inflammatory processes, stigma, psychosocial impact of psoriasis, barriers to care, financial burden of chronic disease, or other related areas.
Due January 13, 2021. Med-RA deadline to receive draft documents: January 4.

Whitehall Foundation Grant Programs<https://urldefense.com/v3/__http://www.whitehall.org/grants/__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzVRcusBQ$ >
It is the Whitehall Foundation’s policy to assist those dynamic areas of basic biological research that are not heavily supported by federal agencies or other foundations with specialized missions. The Whitehall Foundation is currently interested in basic research in neurobiology, defined as follows: Invertebrate and vertebrate (excluding clinical) neurobiology, specifically investigations of neural mechanisms involved in sensory, motor, and other complex functions of the whole organism as these relate to behavior. The overall goal should be to better understand behavioral output or brain mechanisms of behavior. The Whitehall Foundation does not support research focused primarily on disease(s) unless it will also provide insights into normal functioning.
Research Grants
Research grants are available to established scientists of all ages working at accredited institutions in the United States. Applications will be judged on the scientific merit and the innovative aspects of the proposal as well as on the competence of the applicant. Research grants of up to three years will be provided. A renewal grant with a maximum of two years is possible, but it will be awarded on a competitive basis. Research grants will not be awarded to investigators who have already received, or expect to receive, substantial support from other sources, even if it is for an unrelated purpose. Research grants normally range from $30,000 to $75,000 per year.
Grants-in-Aid
The Grants-in-Aid program is designed for researchers at the assistant professor level who experience difficulty in competing for research funds because they have not yet become firmly established. Grants-in-Aid can also be made to senior scientists. All applications will be judged on the scientific merit and innovative aspects of the proposal, as well as on past performance and evidence of the applicant’s continued productivity. Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.
Letter of intent due January 15, 2021; April 15, 2021; and October 1, 2021. Med-RA deadline to receive draft documents for January 2021 due date: January 4.

Hope Foundation for Cancer Research: SWOG/Hope Foundation Impact Award<https://urldefense.com/v3/__https://thehopefoundation.org/research-funding/juried-programs/swog-hope-foundation-impact-award/__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzoWnM8QI$ >
The SWOG/Hope Foundation Impact Award is a funding program that encourages novel and innovative SWOG research by supporting early and conceptual stages of these projects. The work proposed should use resources from completed SWOG trials or be directly translatable to future clinical trials in SWOG and the National Clinical Trials Network (NCTN). These studies may involve scientific risk but potentially lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research.
Letter of intent due January 15, 2021. Med-RA deadline to receive draft documents: January 4.

NHLBI Program Project Applications (P01 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-088.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzRKq8t8g$ >
This Funding Opportunity Announcement (FOA), issued by the National Heart, Lung, and Blood Institute (NHLBI) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Programs may also include implementation science, health disparities, and translation research that addresses the mission of the Institute. Each application submitted in response to this FOA must include at least three related research projects that share a common central theme, focus, and/or overall objective. Higher budgets may be requested for applications that include at least four projects, one of which includes an Early Stage Investigator as Project Leader.
Standard dates apply. Expires September 26, 2023. Med-RA deadline to receive draft documents for January 25 standard date: January 11.

Alzheimer’s Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-309.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzb10ASIw$ >
This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer’s disease (AD) and other age-related dementias using the Alzheimer’s disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.
Standard dates apply. Expires January 8, 2024. Med-RA deadline to receive draft documents for February 5 standard date: January 25.

Mood and Psychosis Symptoms during the Menopause Transition (R21 / R01 Clinical Trial Optional)
R21<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-106.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzNTRXjSw$ >
R01<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-105.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzVICectc$ >
The purpose of these Funding Opportunity Announcements is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, research is solicited that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts.
Due February 9, 2021. Med-RA deadline to receive draft documents: January 27.

NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-079.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzqqcRWMI$ >
This Funding Opportunity Announcement (FOA) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI’s mission. The NHLBI expects that applications to this FOA will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this FOA will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://urldefense.com/v3/__https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbz_Q_Y_HU$ ), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.
Standard dates apply. Expires January 8, 2024. Med-RA deadline to receive draft documents for February 16 standard date: February 3.

NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-084.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzwFZ8DAk$ >
This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator­ initiated Research Project Grant (R01) or equivalent application.
Standard dates apply. Expires January 8, 2024. Med-RA deadline to receive draft documents for February 16 standard date: February 3.

NSF: Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH)<https://urldefense.com/v3/__https://www.nsf.gov/pubs/2021/nsf21530/nsf21530.htm__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzOLfjgBY$ >
The purpose of this interagency program solicitation is to support the development of transformative high-risk, high-reward advances in computer and information science, engineering, mathematics, statistics, behavioral and/or cognitive research to address pressing questions in the biomedical and public health communities. Transformations hinge on scientific and engineering innovations by interdisciplinary teams that develop novel methods to intuitively and intelligently collect, sense, connect, analyze and interpret data from individuals, devices and systems to enable discovery and optimize health. Solutions to these complex biomedical or public health problems demand the formation of interdisciplinary teams that are ready to address these issues, while advancing fundamental science and engineering.
Due February 16, 2021; November 10, 2021; and November 10, 2022. Med-RA deadline to receive draft documents for February 2021 due date: February 3.

NSF: Reproducible Cells and Organoids via Directed-Differentiation Encoding (RECODE)<https://urldefense.com/v3/__https://www.nsf.gov/pubs/2020/nsf20541/nsf20541.htm__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzvT97NOk$ >
The National Science Foundation (NSF) Divisions of Chemical, Bioengineering, Environmental and Transport Systems (CBET), Integrative and Organismal Systems (IOS), Molecular and Cellular Biosciences (MCB), and Civil, Mechanical, and Manufacturing Innovation (CMMI) seek proposals that elucidate mechanisms of, and develop strategies to, direct the differentiation of undifferentiated cells into mature, functional cells or organoids. Projects responsive to this solicitation must aim to establish a robustly validated and reproducible set of differentiation design rules, mechanistic models, real-time sensing, control, and quality assurance methods, and integrate them into a workable differentiation strategy. They must deepen our fundamental understanding of how cells develop and differentiate, providing insights into mechanisms, molecular machinery, dynamics, and cell-cell and cell-extracellular matrix (ECM) interactions, and use this understanding to manipulate cells purposefully. Investigators can choose any undifferentiated cell type from any animal species, including those that may be considered non-model organisms, as a starting point and choose any appropriate functional product (cell, organoid, etc.) with real-world relevance. Collaborative proposals, of a duration up to 4 years, with budgets up to $1,500,000 total will be considered. The solicitation will support teams of three or more PI/co-PIs and senior personnel with complementary expertise. Proposals with only one PI or one PI with one other senior personnel are not permitted and will be returned without review. Reflecting the need for thoughtful collaboration and planning required for these projects, Preliminary Proposals are required to be submitted prior to submission of a full proposal. Topics that reside clearly within the boundaries of a single NSF core program are outside of the scope of this solicitation. Specifically, projects centered around the exploration of individual stages/mechanisms of differentiation in isolation or production of engineered cells, tissues, organ-on-a-chip systems, or organoids without developing an understanding of differentiation rules are not responsive to this solicitation.
Preliminary proposal due February 18, 2021. Med-RA deadline to receive draft documents: February 8.

Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-058.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzAeKfBSU$ >
The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.
Due February 22, 2021; June 22, 2021; February 22, 2022; June 22, 2022; February 22, 2023; and June 22, 2023. Med-RA deadline to receive draft documents for February 2021 due date: February 9.

Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-21-056.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzFbmqhBM$ >
The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, which should include evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.
Due February 22, 2021; June 22, 2021; February 22, 2022; June 22, 2022; February 22, 2023; and June 22, 2023. Med-RA deadline to receive draft documents for February 2021 due date: February 9.

Molecular and Cellular Analysis Technologies (R21 / R33 Clinical Trials Not Allowed)
These funding opportunities are part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program<https://urldefense.com/v3/__https://imat.cancer.gov/__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzntdACm8$ >.
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-003.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzJGJhqkw$ >
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology.
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-ca-21-004.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzHPQR6U4$ >
This Funding Opportunity Announcement (FOA) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer.
Due February 22, 2021; May 27, 2021; and September 29, 2021. Med-RA deadline to receive draft documents for February 2021 due date: February 9.

Biospecimen Science Technologies (R21 / R33 Clinical Trials Not Allowed)
These funding opportunities are part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program<https://urldefense.com/v3/__https://imat.cancer.gov/__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzntdACm8$ >.
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-ca-21-005.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzrU9vXrY$ >
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-ca-21-006.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzC_bsEqE$ >
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.
Due February 22, 2021; May 27, 2021; and September 29, 2021. Med-RA deadline to receive draft documents for February 2021 due date: February 9.

NSF Understanding the Rules of Life: Microbiome Theory and Mechanisms (URoL:MTM)<https://urldefense.com/v3/__https://www.nsf.gov/pubs/2021/nsf21534/nsf21534.htm__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzzNVGVRM$ >
The objective of the Understanding the Rules of Life: Microbiome Interactions and Mechanisms (URoL:MIM) program  is to understand interactions and mechanisms that govern the structure and function of microbiomes. By integrating the wide range of accumulated data and information on microbiome structure and function, new causal models of interactions and interdependencies across scales and systems can be generated. Elucidating these relationships will inform our understanding of the Rules of Life – the theoretical constructs and models that explain and predict the emergent characteristics of living systems, as seen in the robustness, resilience, and adaptability of the individual organisms, populations, and communities. We define a microbiome as a collection of different microbes in a specific habitat. This may include non-host-associated microbiomes and host-associated microbiomes, such as those in humans and other organisms, where i) the microbiome impacts host physiology, behavior, development, and fitness; ii) the host influences the metabolic activity, dynamics and evolution of the microbiome, and iii) the environment (biological, chemical, physical, and social) influences and is influenced by both the host and the microbiome. The URoL:MIM program invites integrated, interdisciplinary proposals that create new knowledge in multiple disciplines to develop causal frameworks with well-designed scientific and/or computational approaches to test hypotheses about the relationships within the microbiome, and among the microbiome, the host, and the environment. Projects may develop new computational, mathematical, or experimental tools, and models, to: i) explain function and interactions in natural, experimental, and model microbiomes; ii) elucidate the chemical and molecular mechanisms that underlie communication between the host and the microbiome and among the members of the microbiome; and/or iii) comparatively analyze characteristics of microbiomes to discover emergent properties that provide insight into the behavior of living systems. URoL:MIM supports basic science research projects of different scales and scope. Projects may have a total budget of up to $3,000,000 and an award duration of up to 5 years.
Due February 23, 2021. Med-RA deadline to receive draft documents: February 10.

Ivy Foundation: Translational Adult Glioma Grant Award<https://urldefense.com/v3/__http://ivyfoundation.org/ivy-foundation-translational-adult-glioma-grant-award/__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzNqfyMTg$ >
The Ben & Catherine Ivy Foundation Emerging Adult Glioma Award provides grant support to investigators conducting high-impact, high-reward translational research for glioma. This award is intended to support projects designed to contribute to identifying therapies that will impact the survival of patients with brain cancer.
$600,000 for two-year projects; 10% IDC.
Due March 1, 2021. Med-RA deadline to receive draft documents: February 16.

Small Vessel VCID Biomarker Validation Consortium Sites (U01)(Clinical Trials Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-005.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzDGByc6A$ >
The purpose of this funding opportunity announcement is to invite applications to an open competition to be one of up to 7 supported sites in the next phase of the NINDS small vessel vascular contributions to cognitive impairment and dementia (VCID) biomarkers consortium. The original consortium pursued initial stages of multi-site validation of 11 candidate imaging-based and fluid-based biomarkers. The primary objective of the next 5 years is to carry out comprehensive multi-site clinical validation of up to six of these 11 biomarkers to be selected by the NINDS in a process separate from this FOA. The focus will be validation in longitudinal studies of diverse all-comers populations that are typical in clinical settings in the United States. The network of sites will provide scientific expertise and experimental infrastructure to pursue these goals synergistically including with the Coordinating Center. At the conclusion of clinical validation each biomarker will have a designated category and context of use as defined by the FDA and a finalized public protocol that describes all details needed to utilize the biomarker. The sites will drive the consortium scientifically and contribute administratively to comprehensive rigorous clinical validation of biomarkers for future clinical trials, including in large phase III trials, and for generating scientific breakthroughs in our understanding and treatment of VCID.
Due March 9, 2021. Med-RA deadline to receive draft documents: February 24.

Pfizer Oncology Investigator Sponsored Research
Overview<https://urldefense.com/v3/__https://www.pfizer.com/purpose/independent-grants/investigator-sponsored-research__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzx9Q_8ME$ > (Also, see attached PDF.)
Qualified researchers are invited to submit investigator-sponsored research (ISR) proposals, according to the guidance and instructions found on the Pfizer ISR portal at https://urldefense.com/v3/__http://www.Pfizer.com/ISR__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzEoWabIQ$ <https://urldefense.com/v3/__https://click.icptrack.com/icp/relay.php?r=42347514&msgid=229405&act=K26I&c=1552564&destination=http*3A*2F*2Fwww.pfizer.com*2FISR&cf=13590&v=cafb85a154fc994c52cdc1ad29285b4d6ee71304eea5819204dec62220c98b38__;JSUlJQ!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzoxyRP_o$ >. All proposals must be submitted via the ISR submission portal. An ISR proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for ISR submissions are made by the applicable Pfizer Global Review Committee. A formal notification regarding the status of your application will be sent on or before the posted notification date. Pfizer support will only be extended upon the execution of an ISR agreement. For any questions, please send an email to GlobalMedicalGrants at pfizer.com<mailto:GlobalMedicalGrants at pfizer.com>. A list of Oncology assets available for ISR proposals, including Areas of Interest, are available on https://urldefense.com/v3/__http://www.Pfizer.com/ISR__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzEoWabIQ$ <https://urldefense.com/v3/__https://click.icptrack.com/icp/relay.php?r=42347514&msgid=229405&act=K26I&c=1552564&destination=http*3A*2F*2Fwww.pfizer.com*2FISR&cf=13590&v=cafb85a154fc994c52cdc1ad29285b4d6ee71304eea5819204dec62220c98b38__;JSUlJQ!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzoxyRP_o$ >. We are also announcing, as of January 2021, the addition of sasanlimab (anti-PD-1) to the list of available oncology products for independent investigation.
Due March 31, 2021; June 30, 2021; October 8, 2021; and January 6, 2022. Med-RA deadline to receive draft documents for March 2021 due date: March 18.

Viatris Investigator Initiated Trials<https://urldefense.com/v3/__https://viatris-iit.steeprockinc.com/__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzc-ZZbsY$ >
Viatris is proud to support independent clinical research conducted by qualified investigators to continue setting new standards in healthcare.  In supporting studies that increase scientific knowledge or clinical evidence, Viatris can continue to address unmet medical needs by way of Investigator Initiated Trials (IITs). An IIT is a clinical study designed and managed independently of Viatris.  The Principal Investigator (PI) assumes full responsibility for the design, ethics and conduct as well as reporting of the study.  Viatris may support IIT initiatives by providing funding, drug product or a combination of both.
Submit concept papers any time. Med-RA deadline to receive draft documents: Ten business days before submission to sponsor.

Multidisciplinary Studies of HIV/AIDS and Aging (R21 / R01 Clinical Trial Optional)
R21<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-069.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzc8ZMjkc$ >
R01<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-068.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzJ8l09EQ$ >
These FOAs encourage applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science.
Standard dates apply. Expires January 8, 2024. Med-RA deadline to receive draft documents for May 7 standard date: April 26.

Informatics for Cancer Research and Management (R21 / U01 / U24)
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-013.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbz-3SErzk$ >
The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research<https://urldefense.com/v3/__http://itcr.cancer.gov__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbz0oOPcyU$ > (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge. In order to be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field.
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-014.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzPHpr39Q$ >
The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research<https://urldefense.com/v3/__http://itcr.cancer.gov/__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzNL-PGvU$ > (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-015.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbz1VendcE$ >
The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR<https://urldefense.com/v3/__https://itcr.cancer.gov/__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbz6f9YVBk$ >) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-016.html__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbzxdoOIV8$ >
The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR<https://urldefense.com/v3/__https://itcr.cancer.gov/__;!!PhOWcWs!lAAtqxiNCvm_rz2JbLF2lo3l0n8XF9f4zpr82E7PmqN4eFG5wDDRjICvnENFH9M5VRnGYB_QyYbz6f9YVBk$ >) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.
Due June 8, 2021 and November 17, 2021. Med-RA deadline to receive draft documents for June 2021 due date: May 25.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20201210/b03c5f54/attachment.html>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: Pfizer Oncology Assets.pdf
Type: application/pdf
Size: 139378 bytes
Desc: Pfizer Oncology Assets.pdf
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20201210/b03c5f54/attachment.pdf>